Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (859)	11/6/1997 11:01:00 PM
From: Pancho Villa	Read Replies (1) \| Respond to of 1359

Neuro >>Thank you for sharing that link. It made Seinfeld look like an Ingmar Bergman film<< You are welcome. >>if one were truly trying to move valued assets out of IPIC into ITRC for example, why would IPIC signal their intentions by starting with a minimal value asset like Transcell? I'll tell you what; if we see a press release announcing that InterCardia has purchased the rights to CerAxon and pagoclone, allowing Interneuron to focus all of its energies upon PMS Escape.....then we can pursue this particular rich fantasy together.<< Perhaps [and I haven't check that facts] the Transcell assets though minimal may be tangible and usable for research purposes. The monetary value of CerAxon and Pagoclone is is very fuzzy at this point. In addition, if these drugs have any future; work on them could be resumed by the same talent under a different registration beyond the reach of the diet pill lawyers with no need of asset transfer. >>However, we are talking about a far higher incidence of baseline valvular anomalies than anticipated (the FDA had cited 1-2% when claiming a fifteenfold increase in the odds of valvular anomalies associated with fluramines). And since Body Mass Index was not positively correlated with valvular regurgitation in the Framingham report, one cannot presume that they somehow had found 10.5% of the group using a fluramine drug. Integrate the recent WSJ sampling of diet doctors who reported an 8% rate of echocardiogram anomalies in fluramine users, with this higher than predicted baserate in the general population, and one ends up with what appears to be a wash, a correlational and liability non-event.<< I guess another logical conclusion is that the guys at the Mayo clinic are just full of BS... Pancho